文献速递白血病造血干细胞移植与细胞治疗

IAC方案治疗复发/难治急性髓系白血病:前瞻性随机对照研究

[Efficacy and safety of IAC regimen for relapse/refractory acute myeloid leukemia: a prospective randomized controlled study].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2022-01-01

前瞻性随机对照试验纳入42例复发/难治急性髓系白血病(AML)患者,IAC组22例、对照组20例。IAC组与医师经验选择方案组的总有效率、完全缓解率及生存差异均无统计学意义;IAC组粒细胞缺乏持续时间更长。结论认为IAC方案疗效与安全性同经验方案相似,患者应尽早行异基因造血干细胞移植(allo-HSCT)。

要点

  • IAC组与对照组总有效率71.4%对40.0%、完全缓解率66.7%对40.0%,差异均无统计学意义。
  • IAC组化疗后粒细胞缺乏中位20天,长于对照组的14天(P=0.023)。
  • 移植组1年总生存率87.5%,明显高于未移植组的6.3%(P<0.001)。

核心结论

  • IAC方案与根据医师经验选择的方案治疗复发/难治AML具有相似的疗效及安全性。
  • 复发/难治AML患者应及早进行allo-HSCT,以期获得长期生存。

研究设计与样本

  • 前瞻性随机对照临床试验,注册号NCT02937662。
  • 纳入2016年7月1日至2019年10月9日于中国医学科学院血液病医院确诊的除急性早幼粒细胞白血病以外的复发/难治AML患者。
  • 入组患者分层随机分组,试验组22例采用IAC方案再诱导治疗,对照组20例由医师根据经验从多个再诱导方案中选择。
  • 符合条件患者在挽救治疗后尽可能进行allo-HSCT。
  • 共42例患者入组,中位年龄36(15~58)岁。

主要发现

  • 总有效率IAC组71.4%对对照组40.0%(P=0.062),完全缓解率IAC组66.7%对对照组40.0%(P=0.121)。
  • 中位随访时间10.5(1.7~32.8)个月;中位总生存时间IAC组14.1(0.6~49.1)个月对对照组9.9(2.0~53.8)个月(P=0.305)。
  • 1年总生存率IAC组54.5%(95%CI 33.7%~75.3%)对对照组48.2%(95%CI 25.9%~70.5%),差异无统计学意义(P=0.305)。
  • 3~4级血液学不良反应发生率IAC组100%(22/22)对对照组95%(19/20);化疗后粒细胞缺乏持续中位时间IAC组20(8~30)天对对照组14(5~50)天(P=0.023)。
  • 早期复发(12个月内复发)组完全缓解率46.7%对晚期复发(12个月后复发)组72.7%(P=0.17),中位总生存时间9.9(1.7~53.8)个月对19.3(0.6~40.8)个月(P=0.420),1年总生存率45.3%(95%CI 27.2%~63.3%)对66.7%(95%CI 40.0%~93.4%)(P=0.420),差异均无统计学意义。

关键数值与推荐

  • IAC方案组成:去甲氧柔红霉素、阿糖胞苷联合环磷酰胺。
  • 主要血液学不良反应为贫血、血小板减少和中性粒细胞减少。
  • 复发/难治AML患者应及早进行allo-HSCT。

临床怎么用

  • 作者认为IAC方案是复发/难治AML耐受良好且有效的方案,与医师经验选择的方案疗效及安全性相似。
  • 作者建议复发/难治AML患者应及早进行allo-HSCT,以期获得长期生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and toxicity profiles of idarubicin, cytarabine, and cyclophosphamide (IAC) in relapse/refractory acute myeloid leukemia (AML) . Methods: This study was a prospective, randomized controlled clinical trial with the registration number NCT02937662. The patients were randomly divided into two groups. The experimental group was treated with an IAC regimen, and the regimen of the control group was selected by doctors according to medication experience. After salvage chemotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was conducted as far as possible according to the situation of the patients. We aimed to observe the efficacy, safety, and toxicity of the IAC regimen in relapse/refractory AML and to explore which is the better regimen. Results: Forty-two patients were enrolled in the clinical trial, with a median age of 36 years (IAC group, 22 cases and control groups, 20 cases) . ①The objective response rate was 71.4% in the IAC group and 40.0% in the control group (P=0.062) ; the complete remission (CR) rate was 66.7% in the IAC group and 40.0% in the control group (P=0.121) . The median follow-up time of surviving patients was 10.5 (range:1.7-32.8) months; the median overall survival (OS) was 14.1 (range: 0.6-49.1) months in the IAC group and 9.9 (range: 2.0-53.8) months in the control group (P=0.305) . The 1-year OS was 54.5% (95%CI 33.7%-75.3%) in the IAC group and 48.2% (95%CI 25.9%-70.5%) in the control group (P=0.305) , with no significant difference between these two regimens. ②The main hematologic adverse events (AEs) were anemia, thrombocytopenia, and neutropenia. The incidence of grade 3-4 hematologic AEs in the two groups was 100% (22/22) in the IAC group and 95% (19/20) in the control group. The median time of neutropenia after chemotherapy in the IAC group and control group was 20 (IQR: 8-30) and 14 (IQR: 5-50) days, respectively (P=0.023) . ③The CR rate of the early relapse (relapse within 12 months) group was 46.7% and that of the late relapse (relapse after 12 months) group was 72.7% (P=0.17) . The median OS time of early recurrence was 9.9 (range:1.7-53.8) months, and that of late recurrence patients was 19.3 (range: 0.6-40.8) months (P=0.420) , with no significant differences between the two groups. The 1-year OS rates were 45.3% (95%CI 27.2%-63.3%) and 66.7% (95%CI 40.0%-93.4%) , respectively (P=0.420) . Survival analysis showed that the 1-year OS rates of the hematopoietic stem cell transplantation group and non-hematopoietic stem cell transplantation group were 87.5% (95%CI 71.2%-100%) and 6.3% (95%CI 5.7%-18.3%) , respectively. The OS rate of the hematopoietic stem cell transplantation group was significantly higher than that of the non-hematopoietic stem cell transplantation group (P<0.001) . Conclusion: The IAC regimen is a well-tolerated and effective regimen in relapsed/refractory AML; this regimen had similar efficacy and safety with the regimen selected according to the doctor's experience for treating relapsed/refractory AML. For relapsed/refractory patients with AML, allogeneic hematopoietic stem cell transplantation should be attempted as soon as possible to achieve long-term survival. 目的: 评估去甲氧柔红霉素、阿糖胞苷联合环磷酰胺(IAC)方案治疗复发/难治急性髓系白血病(AML)的疗效和安全性。 方法: 研究设计为前瞻性随机对照临床试验。纳入2016年7月1日至2019年10月9日于中国医学科学院血液病医院确诊的除急性早幼粒细胞白血病以外的复发/难治AML患者。入组患者进行分层随机分组,试验组选择IAC方案再诱导治疗,对照组的治疗方案由医师根据经验从多个再诱导治疗方案中选择。符合条件患者在挽救治疗后尽可能进行异基因造血干细胞移植(allo-HSCT)。分析两组的疗效及安全性。 结果: 42例患者入组,IAC组22例,对照组20例,中位年龄为36(15~58)岁。①两组患者总有效率(ORR)分别为71.4%和40.0%(P=0.062);完全缓解(CR)率分别为66.7%和40.0%(P=0.121)。中位随访时间为10.5(1.7~32.8)个月,IAC组中位总生存(OS)时间为14.1(0.6~49.1)个月,对照组为9.9(2.0~53.8)个月(P=0.305)。1年OS率两组分别为54.5%(95%CI 33.7%~75.3%)和48.2%(95%CI 25.9%~70.5%),差异无统计学意义(P=0.305)。②不良反应主要表现为骨髓抑制导致的血细胞减少。IAC组和对照组3~4级血液学不良反应发生率分别为100%(22/22)和95%(19/20)。化疗后粒细胞缺乏持续的中位时间分别为20(8~30)d和14(5~50)d(P=0.023)。③早期复发(12个月内复发)组CR率为46.7%,晚期复发(12个月后复发)组CR率为72.7%(P=0.173),两组中位OS时间分别为9.9(1.7~53.8)个月和19.3(0.6~40.8)个月(P=0.420),1年OS率分别为45.3%(95%CI 27.2%~63.3%)和66.7%(95%CI 40.0%~93.4%)(P=0.420),差异均无统计学意义。④对于挽救治疗后的患者,根据是否接受allo-HSCT分组,移植组和未移植组1年OS率分别为87.5%(95%CI 71.2%~100%)和6.3%(95%CI 5.7%~18.3%),移植组明显高于未移植组(P<0.001)。 结论: IAC方案与根据经验选择的方案对复发/难治AML患者具有相似的疗效及安全性,复发/难治患者应及早进行allo-HSCT,以期获得长期生存。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li CH, Wei SN, Qiu SW, et al. [Efficacy and safety of IAC regimen for relapse/refractory acute myeloid leukemia: a prospective randomized controlled study]. Zhonghua Xue Ye Xue Za Zhi. 2022. PMID: 35680626. doi:10.3760/cma.j.issn.0253-2727.2022.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。